Edition:
United States

CombiMatrix Corp (CBMX.OQ)

CBMX.OQ on NASDAQ Stock Exchange Capital Market

4.85USD
24 Mar 2017
Change (% chg)

$0.15 (+3.19%)
Prev Close
$4.70
Open
$4.75
Day's High
$5.10
Day's Low
$4.75
Volume
30,519
Avg. Vol
30,421
52-wk High
$5.20
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Lipka Michael Andrew reports 6.1 pct passive stake in Combimatrix as of Feb 23- SEC filing
Friday, 3 Mar 2017 11:10am EST 

Combimatrix Corp:Lipka Michael Andrew reports 6.1 percent passive stake in Combimatrix Corp as of feb 23, 2017- SEC filing.  Full Article

CombiMatrix Corporation Q4 loss per share $0.22
Wednesday, 22 Feb 2017 04:05pm EST 

CombiMatrix Corporation : CombiMatrix Corporation reports 2016 fourth quarter and full year financial and operating results . Q4 loss per share $0.22 .Q4 revenue rose 32 percent to $3.5 million.  Full Article

Combimatrix reports agreement with Universal Labs
Wednesday, 10 Aug 2016 06:00am EDT 

Press Release : Combimatrix announces distribution agreement with universal diagnostic laboratories for miscarriage analysis testing .Combimatrix corp says terms of agreement were not disclosed.  Full Article

Combimatrix Reports Q2 loss per share $0.89
Wednesday, 3 Aug 2016 04:05pm EDT 

Combimatrix Corp : Q2 revenue rose 22 percent to $3.1 million . Combimatrix corporation reports second quarter 2016 financial and operating results .Q2 loss per share $0.89.  Full Article

CombiMatrix Corp prices $8 mln underwritten public offering
Monday, 21 Mar 2016 08:12am EDT 

CombiMatrix Corp:Says has priced a firm commitment underwritten public offering of 8,000 units of Series F convertible preferred stock.Offering is expected to close on or about March 24, 2016.Each unit consists of one share of Series F convertible preferred stock, which is convertible into 258.397875 shares of common stock at a conversion price of $3.87 per share.In total, the Series F convertible preferred stock is convertible into 2,067,183 shares of common stock, and the warrants are exercisable for 2,067,183 shares of common stock.Company will use part of the proceeds from this offering to repurchase and retire its Series E convertible preferred stock.  Full Article

New data from CombiMatrix Corp study support follow-up diagnostic testing to confirm positive results from non-invasive prenatal testing
Friday, 9 Oct 2015 06:00am EDT 

CombiMatrix Corp:New data from Combimatrix study support follow-up diagnostic testing to confirm positive results from non-invasive prenatal testing.Overall true positive and false positive rates for nipt versus diagnostic testing were estimated at about 70 pct. and 20 pct., respectively.Says data show significant false positive rates for microdeletions.  Full Article

More From Around the Web

BRIEF-CombiMatrix Corporation Q4 loss per share $0.22

* CombiMatrix Corporation reports 2016 fourth quarter and full year financial and operating results